We recently published a list of 10 Best Rated Penny Stocks To Buy According to Analysts. In this article, we are going to take a look at where Protalix BioTherapeutics, Inc. (NYSE:PLX) stands against the other best rated penny stocks.
Penny stocks, often defined as shares trading for less than $5, present a high-risk, high-reward investment opportunity. These stocks, typically from smaller or emerging companies, can offer significant upside potential but come with substantial volatility and limited liquidity. Investors are drawn to penny stocks for their potential to deliver substantial gains with relatively small initial investments. In this article, we will explore ten highly rated penny stocks, as recommended by analysts, which stand out for their promising prospects and potential for strong returns. As we dive into the world of penny stocks, it’s important to consider the broader economic backdrop shaping investment opportunities. The latest Q2 2024 economic forecast for the United States reveals a generally positive outlook, buoyed by resilient consumer spending, strong business investments, and a robust job market. Despite these strengths, challenges such as geopolitical tensions and lingering inflation concerns cast a shadow over the financial landscape.
Deloitte’s recent analysis highlights that, although the US economy has exceeded growth expectations amidst high interest rates and global economic slowdowns, real GDP growth is showing signs of moderation. Policymakers have adeptly navigated the risk of a recession, and inflation is inching closer to the 2% target. With consumer spending expected to remain strong through the first half of 2024, driven by a favorable labor market and steady business and government expenditures, the short-term economic outlook appears promising. However, potential risks loom, including geopolitical conflicts and trade disruptions that could lead to prolonged inflation and possibly further rate hikes by the Federal Reserve. Deloitte’s baseline scenario forecasts a real GDP growth rate of 2.4% for 2024, with a gradual slowdown to 1.1% in 2025. Despite these uncertainties, the US economy is set to outpace many global markets in the near term, with imports and exports experiencing moderate growth.
Despite recent financial market turbulence and weaker economic data, fears of a US recession are exaggerated. The labor market has softened, but the economy is still advancing at a moderate pace. EY anticipate slower growth into 2025 due to high prices and interest rates impacting private sector activity. Households are expected to spend more cautiously, and businesses will be more selective with hiring and investment. However, financial market volatility is more about the Fed’s delayed policy adjustments than a fundamental economic weakness. A 2.5% real GDP growth is anticipated for 2024, with a decrease to 1.7% expected in 2025. The labor market shows signs of cooling, with July’s jobs report revealing a disappointing 114,000 new jobs and reduced wage growth. The unemployment rate rose to 4.3%, and further increases are expected, potentially reaching 4.5% by 2025, driven by tight monetary policy. Consumer spending remains resilient, bolstered by a strong July retail sales report, but is expected to slow due to softer labor market conditions and high living costs. Consumer spending growth is forecasted to decelerate to 2.2% in 2024 and 1.8% in 2025. Inflation pressures are easing, with July’s CPI showing modest increases. Headline CPI inflation has dropped to 2.9% year-over-year, and core CPI inflation is at 3.2%. This trend should continue, with headline CPI projected at 2.6% by Q4 2024. The Federal Reserve is expected to implement three rate cuts in 2024 due to ongoing disinflation and a cooling labor market. EY anticipate 25 basis point cuts in September, November, and December. Risks include potential inflation from sticky services prices, commodity spikes, and global trade issues. Upside risks involve non-inflationary growth from technological advancements, including generative AI.
As indicated above, recent forecasts show a slowdown in economic growth, with real GDP expected to expand at a slower pace next year compared to the robust growth in 2023, reflecting the cumulative impact of high interest rates and diminishing pandemic-era economic stimuli. Consumer spending, a key driver of economic activity, is anticipated to grow more slowly due to reduced excess savings and moderating wage gains. Despite a backdrop of moderate inflation and cooling housing market activity, opportunities in the penny stock sector may emerge as investors seek high growth potential in smaller, undervalued companies. Analysts are pinpointing specific penny stocks that could capitalize on these economic dynamics, offering potentially high returns amidst the broader economic landscape. In this article, we delve into the top rated penny stocks recommended by analysts, each presenting unique opportunities as the economic landscape evolves.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture.
Protalix BioTherapeutics, Inc. (NYSE:PLX)
Upside Potential: 1,422%
Average Analyst Share Price Target: $14
Protalix BioTherapeutics, Inc. (NYSE:PLX) is a biopharmaceutical company based in Carmiel, Israel, that specializes in developing recombinant therapeutic proteins using a plant cell-based expression system called ProCellEx. The company’s key products include Alidornase alfa, PRX-115, and PRX-11. Protalix was founded by Yoseph Shaaltiel in 1993. Protalix BioTherapeutics, Inc. (NYSE:PLX) showcases an impressive upside potential of 1,422%, indicating a highly optimistic outlook from analysts.
In their Q2 2024 earnings call, Protalix BioTherapeutics, Inc. (NYSE:PLX) reported an EPS of -$0.03, missing expectations by $0.05, and revenue of $13.30 million, which, despite a 62.07% year-over-year decline, exceeded expectations by $804,000. The company provided updates on its ongoing clinical programs, particularly focusing on PRX-115, a recombinant PEGylated Uricase candidate for treating uncontrolled gout. The Phase 1 clinical study showed promising results, leading to the expansion of the study to include an eighth cohort. Protalix is preparing for a Phase 2 trial, expected to commence in mid-2025. Protalix BioTherapeutics, Inc. (NYSE:PLX) collaboration with Chiesi Global Rare Diseases, focusing on the commercialization of Elfabrio, remains strong, with Chiesi’s continued investment in the rare disease space. Additionally, Protalix is expanding its R&D efforts, particularly in renal rare diseases, leveraging its ProCellEx platform. The company is also exploring other modalities, such as small molecules and oligonucleotides, to diversify its product pipeline.
Financially, Protalix BioTherapeutics, Inc. (NYSE:PLX) recorded a decrease in revenue from selling goods by $1.8 million compared to the previous year, primarily due to decreased sales to Chiesi, though partially offset by increased sales to Brazil and Pfizer. The company’s R&D expenses decreased by 33%, largely due to the completion of the Fabry clinical program. Despite a net loss of $2.2 million for the quarter, Protalix BioTherapeutics, Inc. (NYSE:PLX) maintains a strong cash position, enabling the repayment of its convertible notes due in September 2024 and supporting ongoing operations. The company is optimistic about its future prospects, focusing on innovation and long-term value creation for both patients and shareholders.
Overall, PLX ranks 2nd on our list of the best rated penny stocks to buy. While we acknowledge the potential of PLX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than PLX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.